Offering New Hope to Cancer Patients and Their Caregivers

A New Frontier in Cancer Therapy What makes us a life-changing biotech

Technology Based on Pancreatic Enzyme Therapy

Our long-term therapy is based on a pancreatic proenzyme formulation that suppresses tumor recurrence and metastasis.

How Our Technology Works

Halting Cancer Cells’ Ability to Invade and Metastasize

PRP, our lead candidate, controls cancer cell migration, inhibits tumor blood vessel formation and triggers the cell’s death.

How PRP Works

Latest Developments

Propanc Biopharma Initiates Development of Bio-Analytical Assay in Preparation for Human Trials

Propanc Biopharma Commences Drug Discovery Research Collaboration

Significant Market Opportunity for Cancer Therapy

80% of all cancers are solid tumors. We are initially targeting pancreatic, ovarian and colorectal tumors.

View the market need for solid tumors

Stock Information | View Detailed Stock Info

OTCQB: PPCB Propanc Biopharma, Inc.
Change
Volume
Day Range
52 Week Range

BIO CEO & Investor Conference Presentation

Investor Presentation

Get Email Alerts

Stay informed about our latest news and updates